A new study has found that people with osteoporosis may experience less protection and be subject to more bone fractures when treated with the drug risedronate. Patients who were treated with risedronate during a drug holiday experienced more hip and other fractures than patients given other medications. Drug holidays are recommended after three to five years on therapy for most people taking bisphosphonates for osteoporosis. Risedronate, with its shorter half-life compared with alendronate, is associated with a somewhat higher risk of hip fracture during a drug holiday.